Newer cardiac troponin I assays have similar performance to troponin T in patients with end-stage renal disease.
BACKGROUND
Troponin T is present in the blood of a majority of patients with endstage renal disease (ESRD) undergoing regular dialysis and presence of troponin T is a predictor of adverse outcome in these patients. With several new formulations of troponin I assays available, this study was performed to see whether these newer assays were able to detect troponin I in these patients more effectively than the older assays.


METHODS
One hundred and forty-three patients undergoing regular haemodialysis or peritoneal dialysis had plasma collected and troponin T and troponin I measured by a variety of assays.


RESULTS
The newer troponin I assays (Abbott Architect, Bayer Centaur and Beckman Accu-TnI) were able to detect troponin I (>75% of samples) as effectively as the Roche assay was able to detect troponin T, while other troponin I assays had a much lower rate of detection of troponin - DPC Immulite 2000 16% and Abbott AxSYM 35%. However, the troponin T assay had more samples detected at concentrations corresponding to an assay CV of 10% (59% of samples) than did the newer troponin I assays (highest on the Bayer Centaur at 37%).


CONCLUSIONS
Newer assays demonstrate that troponin I is present in a similar number of samples as is troponin T, in the blood of patients with dialysis-dependent renal failure, and these newer troponin I assays identify patients at risk of experiencing a cardiac event.
Hickman
Peter E
PE
ANU Medical School, Canberra, Australia. peter.hickman@act.gov.au
Koerbin
Gus
G
Southcott
Emma
E
Tate
Jill
J
Dimeski
Goce
G
Carter
Andrew
A
McGill
Darryl
D
Talaulikar
Girish
G
Potter
Julia M
JM
D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000628:therapy; D006435:Renal Dialysis; D012680:Sensitivity and Specificity; D019210:Troponin I / Q000097:blood*; D020107:Troponin T / Q000097:blood*
D019210:Troponin I; D020107:Troponin T